Edaravone / Radicava - a powerful antioxidant

#1

anyone tried it? suitable for ITP?

  • cyclic dosing and fasting administration;
  • potentially serious hypersensitivity reactions;
  • sulfite-related reactions;
1 Like
#2

Edaravone (Radicava): Evidence Summary

What it is

Edaravone (MCI-186; brands Radicava IV, Radicava ORS oral suspension, Radicut in Japan) is a low-molecular-weight free-radical scavenger. It neutralizes both water- and lipid-soluble peroxyl radicals and peroxynitrite, and in cell/animal work also corrects mislocalization of TDP-43 (an aggregation-prone protein central to ALS pathology) — so its action is not purely antioxidant.

Approved indications (strongest evidence)

ALS — FDA-approved IV in May 2017, oral suspension (ORS) in 2022. Approval rested on the pivotal Phase 3 Study 19 (MCI186-19): in an enriched population (early disease, rapid progression, FVC ≥80% predicted), edaravone slowed functional decline by 2.49 ALSFRS-R points vs placebo over 24 weeks — statistically significant. Notably, an earlier unenriched trial (Study 16) was negative; the benefit only emerged after enrichment, which is the central caveat on the ALS efficacy story.

Acute ischemic stroke — approved in Japan since 2001 (not FDA-approved for this). A 252-patient Phase 3 RCT showed improved modified Rankin outcomes vs placebo (p=0.038), sustained at 3/6/12 months. Japanese guidelines give it a Class B recommendation. Independent reviewers have called the stroke trial evidence methodologically limited.

Survival / “life extension” — the human data

This is where the life-extension question actually lives, and the evidence is suggestive but not definitive (mostly real-world/observational and manufacturer-linked, not placebo RCT survival endpoints):

  • Administrative claims analysis: median survival 29.5 vs 23.5 months; 27% lower death risk (HR 0.73, 95% CI 0.59–0.91).
  • ALS/MND Natural History Consortium (ENCALS 2024): edaravone + riluzole added ~3+ months vs riluzole alone.
  • Meta-analysis: improved survival rates at 18, 24, and 30 months.
  • Radicava ORS vs matched historical controls (PRO-ACT): reported large hazard reductions and ~7.3-month survival prolongation — but propensity-matched to historical placebo, not a randomized survival trial.

Important nuance: the Phase 3b MT-1186-A02 study did not fail against placebo — it compared once-daily vs the approved on/off dosing and found them equivalent, confirming the current regimen.

Geroscience / aging — the weakest link

There is no evidence edaravone extends lifespan in whole-organism aging models (no C. elegans/Drosophila/mammalian lifespan data). What exists is healthspan-flavored, mechanism-level preclinical work:

  • Alzheimer’s model (APP/PS1 mice, PNAS): reduced Aβ burden, oxidative stress, neuroinflammation, tau hyperphosphorylation; rescued cognition.
  • Reproductive/oocyte aging (mice): 10 nM edaravone reduced meiotic abnormalities and ROS, improved mitochondrial function in aged oocytes.
  • Skeletal muscle: protected myoblasts and aided regeneration after ischemic injury in ob/ob mice.

The broader caveat a geroscientist should flag: the oxidative-stress theory of aging is not robustly supported — unbiased screens repeatedly fail to find antioxidants among lifespan-extending compounds. So edaravone’s radical-scavenging mechanism is a weak a priori basis for expecting longevity effects.

Safety

Generally well tolerated. Main concerns: infusion/hypersensitivity reactions (IV), sulfite content (sodium bisulfite → caution in sulfite-sensitive/asthmatic patients), and treatment burden. Large post-marketing stroke surveillance (>500,000 patients in Japan) showed low adverse-event rates; rare acute kidney injury has been reported.

Bottom line

Solid, regulator-grade evidence supports slowing functional decline in a defined ALS subgroup. Survival benefit is plausible and consistently pointing in the right direction, but rests on observational/historical-control data, not randomized survival endpoints. As a general geroprotective or life-extension agent, the evidence is essentially absent— only mechanistic, disease-specific healthspan signals in aged-tissue models, against a theoretical backdrop where antioxidants have a poor track record for extending lifespan.

Sources: